The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
Download the full report here.
Citation; Sampson, C., O’Neill, P. & Lorgelly, P. (2018). The Impact of New Medicines in the NHS: 70 Years of Innovation . OHE Consulting Report, London: Office of Health Economics.
Interviewees came from scientific, clinical, practicing, academic, and regulatory backgrounds in the context of new medicines in the UK and are, or were previously, employed by the NHS, the Medicines and Healthcare products Regulatory Agency (MHRA), NICE, universities or non-academic research institutions.
Several interviewees had been employed in industry at some point in their career. Medical fields and specialties of expertise in the group included cardiology, gastroenterology, general practice, infectious disease, paediatrics, psychiatry, respiratory medicine, and surgery.